Evidence map›Paper›PMID 31564834›Full record

ArticleDrug design, development and therapy2019

Omalizumab for chronic spontaneous urticaria in "complex" patients: data from real-life clinical practice.

Laura Vollono, Arianna Piccolo, Caterina Lanna, Maria Esposito, Mauro Bavetta, Elena Campione, Luca Bianchi, Laura Diluvio

Open access · goldAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Drug design, development and therapy, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers.

0numbers the graph read from it
0cells of the map it votes in
4citing papers in PubMed
2.0field-weighted citation impact, top 14% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

4 citing papers in PubMed, 17 citations in OpenAlex.

  1. Review
  2. Review
  3. Anti-IgE for the Treatment of Chronic Urticaria.ImmunoTargets and therapy · 2021
    Review
  4. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors at 2 institutions in 1 country.

Laura VollonoDermatology Department, University of Rome, Tor Vergata, Italy.
Arianna PiccoloDermatology Department, University of Rome, Tor Vergata, Italy.
Caterina LannaDermatology Department, University of Rome, Tor Vergata, Italy.
Maria EspositoDermatology Department, University of L'Aquila, L'Aquila, Italy.
Mauro BavettaDermatology Department, University of Rome, Tor Vergata, Italy.
Elena CampioneDermatology Department, University of Rome, Tor Vergata, Italy.
Luca BianchiDermatology Department, University of Rome, Tor Vergata, Italy.
Laura DiluvioDermatology Department, University of Rome, Tor Vergata, Italy.
University of Rome Tor Vergata · ITUniversity of L'Aquila · IT

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

introductionOmalizumab is a recombinant humanized anti-IgE monoclonal antibody, approved for patients affected by chronic spontaneous urticaria resistant to antihistamines. Although the clinical benefit of omalizumab has been established in several clinical trials, there are very little data about long-term treatment with this drug and real-life reports regarding its use in patients affected by comorbidities other than urticaria are lacking.

objectivesTo assess omalizumab efficacy and safety in a heterogeneous population of patients affected by chronic spontaneous urticaria and several comorbidities in a real-world setting. MATERIALS AND

methodsPatients affected by chronic spontaneous urticaria with weekly urticaria activity score >16 resistant to antihistamines were treated with omalizumab 300 mg injection as add-on to H1-antihistamines administered every 4 weeks for 6 months. Clinical assessment of weekly urticaria activity score, dermatology life quality index and blood tests were performed at baseline, 12, 24 and 52 weeks of treatment. Response was assessed based on reduction weekly urticaria activity score.

resultsThirty-two patients (22F; 10M) with a mean age of 52.4 years (range 27-72) affected by chronic spontaneous urticaria were enrolled. Comorbidities affecting our study population were divided into 6 categories: cardio-metabolic (77%), oncologic (19%), infectious (16%), allergic (45%) immunologic (41%) and others (18%). Omalizumab determined a satisfactory reduction of symptoms of chronic spontaneous urticaria and an amelioration of quality of life within our population. No relevant alterations regarding patients' underlying conditions were encountered. This is the first study regarding the use of omalizumab for chronic spontaneous urticaria in a population of adult patients affected by several comorbidities, eg, cardio-metabolic, oncologic, infectious, allergic, immunologic and psychiatric diseases. Real-life data represent a valuable source of information about a drug's safety and efficacy profile, especially in patients affected by different comorbidities that are widely diffused in Western countries.

Indexed as

AdultAgedAnti-Allergic AgentsChronic UrticariaFemaleHumansInjections, SubcutaneousItalyMaleMiddle AgedOmalizumabQuality of LifeRetrospective StudiesAnti-Allergic AgentsOmalizumaballergic and immunologic conditionscardiovascularchronic spontaneous urticariacomorbiditiesomalizumaboncologic

Identifiers

PMID31564834
PMCPMC6735630
OpenAlexW2971994265

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.